Bmy stock forecast 2025 research desk summaries indicate that

Research desk summaries indicate that BMY stock forecast 2025 depends heavily on U.S. reimbursement stability and international growth, notably from Asia-Pacific oncology markets. Cramer included Bristol-Myers Squibb Company (NYSE:BMY) in his YEV stocks list and mentioned the company’s acquisitions which can bring promising additions to its pipeline. Here’s what he had to say: On Jan. 8, Truist Securities analyst Robyn Karnauskas maintained a “ Buy ” rating while raising the price target to $65, which indicates a 9.9% premium to current price levels. BMY’s 2025 growth outlook remains linked to cell therapy adoption rates, which market models suggest could accelerate topline figures faster than consensus projections.